Prevalence and risk factors of preoperative anxiety in women undergoing cesarean section: A global systematic review and meta-analysis.

Best Pract Res Clin Obstet GynaecolAug 19, 2026 (epub)
Clinical ResearchObstetrics & Gynecology

Mahsa Maghalian, Seyedeh Tahereh Mirmolaei, Mahsan Nabighadim et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prevalence and risk factors of preoperative anxiety in women undergoing cesarean sections, including 24 studies with 3928 participants. The pooled prevalence of preoperative anxiety was found to be 66.7% (95% CI: 58.3-74.5%), with significant variations based on geography and income level.

Key findings

  • Pooled prevalence of preoperative anxiety was 66.7% (95% CI: 58.3-74.5%).
  • Prevalence varied significantly by country, from 25.0% in Malaysia to 98.0% in Turkey.
  • Higher education was associated with increased anxiety (OR=1.67, 95% CI: 1.25-2.22).
  • No significant difference in anxiety was found between elective and emergency cesarean deliveries (p=0.670).

Why it matters

Understanding the prevalence and risk factors of preoperative anxiety in cesarean deliveries is crucial for developing effective screening and intervention strategies, which can improve maternal and neonatal outcomes.

Source

PubMed · PMID 42628488

Published in Best Pract Res Clin Obstet Gynaecol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.